Perspectivas del mercado y visión de analista:
El trastorno por déficit de atención/hiperactividad (TDAH) es un trastorno complejo del desarrollo neurológico que afecta la capacidad de las personas para concentrarse, controlar las conductas impulsivas y gestionar la hiperactividad. Se diagnostica principalmente en la infancia, pero los síntomas pueden persistir hasta la adolescencia y la edad adulta. El tratamiento para el TDAH a menudo implica un enfoque multidisciplinario, que incluye terapia conductual, educación y medicamentos, como estimulantes y no estimulantes.
Factores como la creciente prevalencia del TDAH y un aumento en la demanda de medicamentos para el tratamiento impulsan el crecimiento del mercado. Sin embargo, los efectos secundarios asociados con los medicamentos para el TDAH y su alivio limitado impiden el crecimiento del mercado de terapias para el TDAH.
Impulsores y restricciones del crecimiento:
Según el artículo publicado por los Centros para el Control y la Prevención de Enfermedades (CDC), en febrero de 2022 , aproximadamente 6 millones de niños de entre 3 y 17 años en EE. UU. fueron diagnosticados con TDAH, lo que representa el 9,8% de la población entre 2016 y 2019. Además, según un artículo publicado por PubMed Central en 2022, el TDAH afecta entre el 5 y el 7,2% de niños y entre el 2,5% y el 6,7% de los adultos en todo el mundo. Según estimaciones recientes, la frecuencia de los adolescentes en los EE. UU. es mucho mayor, aproximadamente el 8,7% o 5,3 millones. Aunque tradicionalmente se ha considerado una afección infantil, hasta el 90% de los niños con TDAH siguen presentando síntomas en la edad adulta. También es posible diagnosticarlo en adultos porque el 75% de las personas con TDAH no fueron diagnosticadas previamente durante la infancia, según un estudio de investigación. El TDAH se asocia frecuentemente con condiciones comórbidas como ansiedad, depresión, trastornos del aprendizaje y abuso de sustancias. La presencia de estas comorbilidades aumenta la complejidad del tratamiento, lo que requiere un enfoque multidimensional que aborde tanto los síntomas del TDAH como las condiciones asociadas. Se recomiendan medicamentos como psicoestimulantes y no estimulantes, que pueden ayudar a los niños a controlar los síntomas del TDAH en su vida diaria y pueden ayudar a regular conductas que pueden causar dificultades en diversos aspectos de sus vidas, incluida la vida personal y el rendimiento académico. Por lo tanto, los factores mencionados anteriormente están aumentando la demanda de medicamentos indicados para el TDAH, facilitando la expansión de la cuota de mercado de terapias para el TDAH. Sin embargo, el crecimiento del mercado de terapias para el TDAH está restringido debido al alivio limitado de los síntomas y los efectos secundarios. efectos asociados con el uso de la terapéutica. Los efectos secundarios comunes de los medicamentos psicoestimulantes incluyen disminución del apetito, insomnio, aumento de la ansiedad, aumento de la irritabilidad, dolor de estómago y dolor de cabeza. Cuando los efectos del medicamento desaparecen, los síntomas del TDAH pueden reaparecer, provocando el efecto de "rebote" que puede ser más intenso.
Perspectivas estratégicas
Segmentación y alcance del informe:
El “análisis del mercado de terapias para el TDAH” ha se ha llevado a cabo considerando los siguientes segmentos: tipo de fármaco, grupo de edad y canal de distribución.
Análisis segmentario:
El mercado de terapias para el TDAH, por tipo de fármaco, se segmenta en estimulantes y no estimulantes.
El segmento de medicamentos estimulantes tuvo una mayor participación de mercado de terapias para el TDAH en 2022 y se prevé que registre una CAGR más alta durante 2022-2030.
Mercado de terapias para el TDAH por tipo de fármaco: 2022 y 2030
Según el grupo de edad, las terapias para el TDAH El mercado está segmentado en pediátrico, adolescente y adulto. El segmento pediátrico y adolescente tuvo una mayor participación de mercado en 2022. Se prevé que el segmento de adultos registre una CAGR más alta de 2022 a 2030. En términos de canal de distribución, el mercado de terapias para el TDAH se clasifica en farmacias hospitalarias, farmacias minoristas, y comercio electrónico. En 2022, el segmento de farmacias hospitalarias tuvo la mayor participación de mercado y se prevé que registre la CAGR más alta durante 2022-2030.
Análisis regional:
América del Norte, Europa, Asia Pacífico, América del Sur y Central y Oriente Medio Oriente y África son las principales regiones analizadas para determinar el alcance del informe de mercado de terapias para el TDAH.
En 2022, América del Norte tenía la mayor cuota de mercado mundial. En América del Norte, EE. UU. tenía la mayor participación del mercado en 2022 y se estima que continuará su dominio de 2022 a 2030. El crecimiento del mercado de terapias para el TDAH se debe en gran medida a la alta prevalencia del TDAH en los EE. UU. Según Cingulate, ~6,4 millones de niños y adolescentes de entre 4 y 17 años fueron diagnosticados con TDAH en 2022. Entre ellos, más del 80 % de este grupo recibe tratamiento y alrededor del 65 % experimenta síntomas continuos de TDAH hasta la edad adulta. Además, se espera que la mejora de la asequibilidad para los pacientes, las políticas de reembolso favorables y el mayor conocimiento de los medicamentos actuales impulsen el crecimiento del mercado. Asia Pacífico es el mercado de más rápido crecimiento para el TDAH debido a la presencia de actores clave en la región y varias iniciativas estratégicas. emprendidas para desarrollar y comercializar nuevos productos. Por ejemplo, en junio de 2020, Otsuka Pharmaceutical Co., Ltd. y Otsuka Pharmaceutical Development & Commercialization, Inc. informaron resultados positivos de sus dos ensayos clínicos de fase 3 de seis semanas de duración que evaluaron la eficacia, seguridad y tolerabilidad de la centanafadina oral. Centanafadina es un nuevo fármaco experimental diseñado para tratar a pacientes adultos diagnosticados con TDAH. La compañía también planeó estudiar los efectos de la centanafadina en niños con TDAH y discutir los próximos pasos con la Administración de Alimentos y Medicamentos de EE. UU.
Desarrollos de la industria y oportunidades futuras:
El pronóstico del mercado de terapias para el TDAH puede ayudar a las partes interesadas en este mercado planifiquen sus estrategias de crecimiento. Las iniciativas tomadas por los actores clave que actúan en el mercado se enumeran a continuación:
En septiembre de 2023, Cingulate Inc. anunció los resultados de su estudio de fase 3 sobre la eficacia y seguridad en adultos de su candidato principal, CTx-1301 (dexmetilfenidato), para el tratamiento del TDAH. . La compañía utiliza Precision Timed Release (PTR), su tecnología patentada de plataforma de administración de medicamentos, para construir y avanzar en una línea de productos farmacéuticos de próxima generación. Los resultados se presentaron el 8 de septiembre en el 36.º Congreso Anual de Psicología en Nashville, Tennessee. En marzo de 2022, Noven Pharmaceuticals, Inc., una subsidiaria de propiedad total de Hisamitsu Pharmaceutical Co., Inc., obtuvo la aprobación de la Administración de Medicamentos y Alimentos de EE. UU. (FDA) por su sistema transdérmico XELSTRYM (dextroanfetamina), CII, para el tratamiento del TDAH en adultos y pacientes pediátricos de seis años o más. En julio de 2021, Corium, Inc. lanzó AZSTARYS. Este medicamento innovador combina Serdexmetilfenidato (SDX) y dexmetilfenidato (d-MPH) en los EE. UU. para el tratamiento sintomático en pacientes de 6 años o más. AZSTARYS obtuvo la aprobación de la FDA en marzo de 2021. Comprende una combinación de dos tipos de medicamentos: 70% de profármaco de liberación prolongada de d-MPH SDX (Programa IV) y 30% de d-MPH de liberación inmediata (Programa II). En abril de 2021 , Supernus Pharmaceuticals, Inc. anunció que la FDA de EE. UU. había aprobado Qelbree (cápsulas de liberación prolongada de viloxazina) para tratar el TDAH en pacientes de 6 a 17 años. Panorama competitivo y empresas clave:
Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly y compañía; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Servicios Johnson & Johnson, Inc.; Corio Inc; Adlon Therapeutics LP; y Teva Pharmaceutical Industries Ltd. se encuentran entre los actores clave perfilados en el informe del mercado terapéutico para el TDAH. Estas empresas adoptan estrategias de desarrollo de productos para satisfacer las crecientes demandas de los clientes, lo que les permite mantener su marca.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The digital health market was valued at US$ 28,594.55 billion in 2022.
The ADHD Therapeutics market, by drug type, is segmented into stimulants and non-stimulant drugs. The stimulant drug segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during 2022-2030.
The ADHD Therapeutics market, by end-user, is segmented into hospitals and clinics, providers, payers, and others. In 2022, the hospitals and clinics segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.
Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopment disorder that affects individuals’ ability to focus, control impulsive behaviors, and manage hyperactivity. It is mostly diagnosed in childhood, but symptoms can persist into adolescence and adulthood. Treatment for ADHD often involves a multidisciplinary approach, including behavioral therapy, education, and medication such as stimulants and non-stimulants.
The digital health market majorly consists of the players, including Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. are among the key players profiled in the ADHD therapeutics market.
Key factors driving the increasing prevalence of ADHD, combined with the increased demand for drugs for treatment, is propelling the market.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)